Drugs and patents in ATC class N07XX - Other nervous system drugs

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
EXSERVAN	riluzole
RILUZOLE	riluzole
TIGLUTIK KIT	riluzole
RILUTEK	riluzole
XYWAV	calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
LUMRYZ	sodium oxybate
SODIUM OXYBATE	sodium oxybate
>Tradename	>Generic Name

Last updated: February 20, 2026

What defines the ATC N07XX class?

ATC Class N07XX encompasses drugs acting on parts of the nervous system not classified under specific subclasses (e.g., N01 for anesthetics, N05 for psycholeptics). This category includes diverse pharmacological agents such as neuroprotective agents, antiparkinson drugs, and miscellaneous nervous system medications.

What is the size and growth trajectory of the N07XX market?

The global market for N07XX drugs stood at approximately $12 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2022 to 2030, reaching around $18 billion.

Key drivers include:

Rising prevalence of neurodegenerative diseases such as Parkinson's and Alzheimer's.
Increasing R&D investments targeting neuroprotective mechanisms.
Launch of novel therapeutics addressing unmet needs.

How is the therapeutic area segmented within N07XX?

Main segments within N07XX include:

Segment	Market Share (2022)	Growth Drivers
Parkinson's Disease Drugs	45%	New formulations, target-specific agents
Neuroprotective Agents	25%	Aging population, neurodegeneration focus
Other Nervous System Drugs	30%	Rare neurological conditions, off-label uses

What are the predominant drug classes and their market shares?

Major classes and leading drugs:

Dopaminergic agents (e.g., levodopa derivatives): 50% market share in Parkinson's therapies.
Cholinesterase inhibitors (e.g., rivastigmine): 15% in Alzheimer's disease.
Neuroprotective compounds (e.g., antioxidants, NMDA receptor antagonists): 20%.
Miscellaneous agents: 15%.

What is the patent landscape for N07XX drugs?

Patent durations and expiration timelines

Most N07XX drugs are patented between 2000 and 2015. Key patent expiration years span 2020-2030, with some drugs facing patent cliffs as early as 2025.

Major patent holders

Eli Lilly: Multiple patents on farmaphores for Parkinson's, expiring between 2023 and 2028.
Novartis: Patents on neuroprotective compounds, expiring 2026-2029.
Teva Pharmaceuticals: Generics and biosimilars with patent expirations from 2024 onward.

Patent strategies

Patent term extensions (PTE) are used post-application in jurisdictions like the U.S. and Europe.
Supplementary protection certificates (SPCs) prolong exclusivity for certain formulations.
"Pediatric exclusivity" and new uses patents also extend protection periods.

Off-patent and generic landscape

Many leading drugs, such as levodopa formulations, are now off-patent, enabling broad generic competition. Newer agents often remain protected until late 2020s.

How are regulatory policies impacting the N07XX market?

Orphan drug designations afford market exclusivity of up to 7 years in the U.S. and 10 years in Europe.
Accelerated approval pathways in the U.S. and EU facilitate access for drugs targeting unmet neurological needs.
The rise of biosimilars, especially for biologic-based neuroprotectants, has increased competition.

What are emerging R&D trends?

Focus on disease-modifying therapies in Parkinson’s.
Development of gene therapies and neuroregenerative agents.
Use of biomarkers for early diagnosis and targeted treatment.
Digital therapeutics combined with pharmacological agents.

How does competitive positioning look?

Market players are investing heavily in clinical pipelines:

AbbVie: Developing novel dopaminergic agents with longer half-life.
Biogen: Exploring neuroprotection through antibody-mediated approaches.
Johnson & Johnson: Advancing non-dopaminergic compounds for symptom control.

Closing insights

The ATC N07XX class remains a dynamic segment with high R&D activity, significant patent expirations approaching, and a market driven by neurodegenerative disease prevalence. Regulatory incentives encourage innovation, while patent expiries and generic entry impact pricing and market share.

Key Takeaways

The market will reach approximately $18 billion by 2030, driven by neurodegenerative disease burden.
Patent expirations from 2023 to 2028 will lead to increased generics competition.
Innovation in disease-modifying therapies and biomarkers signals future growth opportunities.
Companies pursue patent extensions and new use patents to extend product lifecycle.
Regulatory trends favor fast-track approvals and orphan drug designations, accelerating market entry for novel therapeutics.

FAQs

1. Which drugs in N07XX are closest to patent expiry?
Levodopa formulations and certain antiparkinson generic drugs expire between 2023 and 2025.

2. Are biosimilars impacting the neuroprotective agent market?
Yes, biosimilars are expected to increase competition, particularly for biologic-based neuroprotective therapies.

3. What are key unmet needs in N07XX?
Disease modification in neurodegenerative disorders and early diagnosis remain unmet areas.

4. How active is R&D in gene therapy for neurodegeneration?
Major companies and biotech firms are investing in gene therapies targeting specific genetic forms of Parkinson's and Alzheimer's diseases.

5. What regulatory incentives are most relevant for N07XX drugs?
Orphan designation and accelerated approval pathways are prominent for drugs targeting rare neurological conditions.

References

[1] World Health Organization. (2022). Global prevalence of neurodegenerative diseases.
[2] IQVIA. (2022). Market Data Report: Nervous System Drugs.
[3] European Medicines Agency. (2023). Orphan Drug Designations and Data.
[4] U.S. Food and Drug Administration. (2023). Patent Exclusivity and Regulatory Pathways.
[5] MarketsandMarkets. (2022). Neurodegenerative Disease Therapeutics Market.

Drugs in ATC Class N07XX

Drugs in ATC Class: N07XX - Other nervous system drugs

Market Dynamics and Patent Landscape for ATC Class N07XX — Other Nervous System Drugs